English

KALOBIOS PHARMACEUTICALS INC

EDGAR

HGEN Quarterly report (10-Q) · filed 2023-05-15

58 filing records in this dataset, filed from 2012-09-25 to 2023-05-15. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

221 thousand USD

2023 Q1 · USD

Exact inputs and evidence

Revenue: 221000 USD Source

Operating margin

-1,916.29%

2023 Q1 · %

Exact inputs and evidence

Operating Income: -4235000 USD Source
Revenue: 221000 USD Source

Operating cash flow

-7.06 million USD

2023 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -7059000 USD Source

Cash and cash equivalents: 3.1 million USD 2023-03-31 Source
Exact value

3096000 USD
Long-term debt including current maturities: 25.2 million USD 2022-03-31 Source
Exact value

25193000 USD
Shares outstanding: 119 million shares 2023-03-31 Source
Exact value

119080135 shares

Reported share-count change

70.23% · 49.1 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

69954377 shares · 2022-03-31· Source
119080135 shares · 2023-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.7 million USD

2022-04-01 – 2023-03-31

Exact inputs and evidence

Revenue: 1036000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 221000 USD · 2022-07-01 – 2022-09-30 Source
Revenue: 2514000 USD · 2022-01-01 – 2022-12-31 Source
Revenue: 2293000 USD · 2022-01-01 – 2022-09-30 Source
Revenue: 221000 USD · 2023-01-01 – 2023-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-05-15.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2022-12-31
Operating income: 11 of 11 periods available· newest 2022-12-31
Net income: 11 of 11 periods available· newest 2022-12-31
Operating cash flow: 11 of 11 periods available· newest 2022-12-31
Capital expenditure: 4 of 11 periods available· newest 2015-12-31
Total assets: 3 of 11 periods available· newest 2022-12-31
Total liabilities: 3 of 11 periods available· newest 2022-12-31
Current assets: 3 of 11 periods available· newest 2022-12-31
Current liabilities: 3 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2021-12-31
Shares outstanding: 3 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-30.1%

Prior period

USD 3.6 million

2021-01-01 – 2021-12-31
Current period

USD 2.51 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

2514000 − 3595000 = -1081000 USD

3595000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
2514000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · KALOBIOS PHARMACEUTICALS INC · 2022-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Year-over-year change in Revenue: -1081000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 2514000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#722448 Filing: 000121465923004512 Input fundies:Revenue: 3595000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#722841 Filing: 000121465923004512
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 165.92 million

Prior period

−USD 236.65 million

2021-01-01 – 2021-12-31
Current period

−USD 70.73 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-70730000 − -236649000 = 165919000 USD

-236649000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-70730000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · KALOBIOS PHARMACEUTICALS INC · 2022-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Year-over-year change in Net income: 165919000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -70730000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#763710 Filing: 000121465923004512 Input fundies:NetIncome: -236649000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#764048 Filing: 000121465923004512
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 107.35 million

Prior period

−USD 184.05 million

2021-01-01 – 2021-12-31
Current period

−USD 76.7 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-76698000 − -184045000 = 107347000 USD

-184045000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-76698000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · KALOBIOS PHARMACEUTICALS INC · 2022-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Year-over-year change in Operating cash flow: 107347000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -76698000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#770688 Filing: 000121465923004512 Input fundies:OperatingCashFlow: -184045000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#771121 Filing: 000121465923004512
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 2.51 million 100% of revenue
Operating costs Derived USD 70.82 million 2,817% of revenue
Operating income −USD 68.3 million −2,717% of revenue
Tax, interest and other Derived USD 2.43 million 96% of revenue
Net income −USD 70.73 million −2,813% of revenue

Cash

Operating cash flow −USD 76.7 million −3,051% of revenue
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 28,369% of revenue.
2021 Operating loss: operating costs were 6,575% of revenue.
2022 Operating loss: operating costs were 2,817% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	312000	88510000 Derived	-88198000	1337000 Derived	-89535000	Unavailable	Source 2020-01-01 – 2020-12-31: 312000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -88198000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -89535000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -69852000 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	3595000	236367000 Derived	-232772000	3877000 Derived	-236649000	Unavailable	Source 2021-01-01 – 2021-12-31: 3595000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -232772000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -236649000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -184045000 USD Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	2514000	70818000 Derived	-68304000	2426000 Derived	-70730000	Unavailable	Source 2022-01-01 – 2022-12-31: 2514000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -68304000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -70730000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -76698000 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 2.5M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	312000	Revenue: 312000 Open source
20212021-12-31	Revenue	3595000	Revenue: 3595000 Open source
20222022-12-31	Revenue	2514000	Revenue: 2514000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-30.1% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 312000 Open source
20212021-12-31	Year over year	1,052.2%	Revenue: 3595000 Open source Revenue: 312000 Open source
20222022-12-31	Year over year	-30.1%	Revenue: 2514000 Open source Revenue: 3595000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -2,716.9% 2022

Net margin -2,813.4% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-28,268.6%	Operating Income: -88198000 Open source Revenue: 312000 Open source
20212021-12-31	Operating margin	-6,474.9%	Operating Income: -232772000 Open source Revenue: 3595000 Open source
20222022-12-31	Operating margin	-2,716.9%	Operating Income: -68304000 Open source Revenue: 2514000 Open source
20202020-12-31	Net margin	-28,697.1%	Net Income: -89535000 Open source Revenue: 312000 Open source
20212021-12-31	Net margin	-6,582.7%	Net Income: -236649000 Open source Revenue: 3595000 Open source
20222022-12-31	Net margin	-2,813.4%	Net Income: -70730000 Open source Revenue: 2514000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 312000 Open source Operating Cash Flow: -69852000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 3595000 Open source Operating Cash Flow: -184045000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 2514000 Open source Operating Cash Flow: -76698000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -76.7M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-69852000	Operating Cash Flow: -69852000 Open source
20212021-12-31	Operating cash flow	-184045000	Operating Cash Flow: -184045000 Open source
20222022-12-31	Operating cash flow	-76698000	Operating Cash Flow: -76698000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -69852000 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -184045000 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: -76698000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

517.7% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	33.3%	Total Liabilities: 22757000 Open source Total Assets: 68302000 Open source
20212021-12-31	Liabilities / assets	133.3%	Total Liabilities: 94749000 Open source Total Assets: 71061000 Open source
20222022-12-31	Liabilities / assets	517.7%	Total Liabilities: 57960000 Open source Total Assets: 11195000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.2× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	3.34×	Current Assets: 68212000 Open source Current Liabilities: 20415000 Open source
20212021-12-31	Current assets / current liabilities	1.03×	Current Assets: 70971000 Open source Current Liabilities: 68725000 Open source
20222022-12-31	Current assets / current liabilities	0.2×	Current Assets: 11105000 Open source Current Liabilities: 56194000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	−USD 41.95 million Exact value Exact value: -41948000 USD 2013-01-01 – 2013-12-31: -41948000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2013-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -41948000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -41948000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000104746914002331/kbio-20131231.xml#990480 Filing: 000104746914002331 The citation records this snapshot. The page link may show a newer release later.	−USD 38.82 million Exact value Exact value: -38815000 USD 2013-01-01 – 2013-12-31: -38815000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2013-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -38815000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -38815000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000104746914002331/kbio-20131231.xml#999209 Filing: 000104746914002331 The citation records this snapshot. The page link may show a newer release later.	USD 344,000 Exact value Exact value: 344000 USD 2013-01-01 – 2013-12-31: 344000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KALOBIOS PHARMACEUTICALS INC · 2013-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Capital Expenditure: 344000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 344000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000104746914002331/kbio-20131231.xml#999912 Filing: 000104746914002331 The citation records this snapshot. The page link may show a newer release later.	−USD 39.16 million Calculation and evidence -38815000 − 344000 USD Exact free cash flow: -39159000 USD 2013-01-01 – 2013-12-31: -38815000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 344000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KALOBIOS PHARMACEUTICALS INC · 2013-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Free cash flow: -39159000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -38815000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000104746914002331/kbio-20131231.xml#999209 Filing: 000104746914002331 Input fundies:CapitalExpenditure: 344000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000104746914002331/kbio-20131231.xml#999912 Filing: 000104746914002331 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 38 million Exact value Exact value: -37998000 USD 2014-01-01 – 2014-12-31: -37998000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2014-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -37998000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -37998000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465916013550/kbio-20151231.xml#213959 Filing: 000121465916013550 The citation records this snapshot. The page link may show a newer release later.	−USD 35.94 million Exact value Exact value: -35939000 USD 2014-01-01 – 2014-12-31: -35939000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2014-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -35939000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35939000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465916013550/kbio-20151231.xml#213580 Filing: 000121465916013550 The citation records this snapshot. The page link may show a newer release later.	USD 448,000 Exact value Exact value: 448000 USD 2014-01-01 – 2014-12-31: 448000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KALOBIOS PHARMACEUTICALS INC · 2014-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Capital Expenditure: 448000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 448000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465916013550/kbio-20151231.xml#217834 Filing: 000121465916013550 The citation records this snapshot. The page link may show a newer release later.	−USD 36.39 million Calculation and evidence -35939000 − 448000 USD Exact free cash flow: -36387000 USD 2014-01-01 – 2014-12-31: -35939000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 448000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KALOBIOS PHARMACEUTICALS INC · 2014-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Free cash flow: -36387000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35939000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465916013550/kbio-20151231.xml#213580 Filing: 000121465916013550 Input fundies:CapitalExpenditure: 448000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465916013550/kbio-20151231.xml#217834 Filing: 000121465916013550 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 35.38 million Exact value Exact value: -35378000 USD 2015-01-01 – 2015-12-31: -35378000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2015-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -35378000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -35378000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465917001799/kbio-20161231.xml#220559 Filing: 000121465917001799 The citation records this snapshot. The page link may show a newer release later.	−USD 29.06 million Exact value Exact value: -29063000 USD 2015-01-01 – 2015-12-31: -29063000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2015-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -29063000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -29063000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465917001799/kbio-20161231.xml#245544 Filing: 000121465917001799 The citation records this snapshot. The page link may show a newer release later.	USD 136,000 Exact value Exact value: 136000 USD 2015-01-01 – 2015-12-31: 136000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · KALOBIOS PHARMACEUTICALS INC · 2015-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Capital Expenditure: 136000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 136000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465917001799/kbio-20161231.xml#246269 Filing: 000121465917001799 The citation records this snapshot. The page link may show a newer release later.	−USD 29.2 million Calculation and evidence -29063000 − 136000 USD Exact free cash flow: -29199000 USD 2015-01-01 – 2015-12-31: -29063000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 136000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · KALOBIOS PHARMACEUTICALS INC · 2015-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Free cash flow: -29199000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -29063000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465917001799/kbio-20161231.xml#245544 Filing: 000121465917001799 Input fundies:CapitalExpenditure: 136000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465917001799/kbio-20161231.xml#246269 Filing: 000121465917001799 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 27.02 million Exact value Exact value: -27019000 USD 2016-01-01 – 2016-12-31: -27019000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2016-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -27019000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27019000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465918002397/hgen-20171231.xml#1130544 Filing: 000121465918002397 The citation records this snapshot. The page link may show a newer release later.	−USD 20.96 million Exact value Exact value: -20961000 USD 2016-01-01 – 2016-12-31: -20961000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2016-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -20961000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -20961000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465918002397/hgen-20171231.xml#1149342 Filing: 000121465918002397 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 21.99 million Exact value Exact value: -21987000 USD 2017-01-01 – 2017-12-31: -21987000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2017-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -21987000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21987000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465919007319/hgen-20190930.xml#818855 Filing: 000121465919007319 The citation records this snapshot. The page link may show a newer release later.	−USD 14.25 million Exact value Exact value: -14249000 USD 2017-01-01 – 2017-12-31: -14249000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2017-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -14249000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14249000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465919007319/hgen-20190930.xml#766974 Filing: 000121465919007319 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 12 million Exact value Exact value: -12004000 USD 2018-01-01 – 2018-12-31: -12004000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2018-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -12004000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12004000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465920005577/hgen-20200331.xml#209051 Filing: 000121465920005577 The citation records this snapshot. The page link may show a newer release later.	−USD 6.21 million Exact value Exact value: -6209000 USD 2018-01-01 – 2018-12-31: -6209000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2018-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -6209000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -6209000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465920005577/hgen-20200331.xml#192894 Filing: 000121465920005577 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 10.29 million Exact value Exact value: -10294000 USD 2019-01-01 – 2019-12-31: -10294000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2019-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -10294000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10294000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465921002990/hgen-20201231.xml#123837 Filing: 000121465921002990 The citation records this snapshot. The page link may show a newer release later.	−USD 4 million Exact value Exact value: -4001000 USD 2019-01-01 – 2019-12-31: -4001000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2019-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -4001000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4001000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465921002990/hgen-20201231.xml#118900 Filing: 000121465921002990 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 89.54 million Exact value Exact value: -89535000 USD 2020-01-01 – 2020-12-31: -89535000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2020-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -89535000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -89535000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/hgen10k1221.htm#1051795 Filing: 000121465922003416 The citation records this snapshot. The page link may show a newer release later.	−USD 69.85 million Exact value Exact value: -69852000 USD 2020-01-01 – 2020-12-31: -69852000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2020-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -69852000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -69852000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465922003416/hgen10k1221.htm#1074497 Filing: 000121465922003416 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 236.65 million Exact value Exact value: -236649000 USD 2021-01-01 – 2021-12-31: -236649000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2021-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -236649000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -236649000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#764048 Filing: 000121465923004512 The citation records this snapshot. The page link may show a newer release later.	−USD 184.05 million Exact value Exact value: -184045000 USD 2021-01-01 – 2021-12-31: -184045000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2021-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -184045000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -184045000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#771121 Filing: 000121465923004512 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 70.73 million Exact value Exact value: -70730000 USD 2022-01-01 – 2022-12-31: -70730000 USD Inspect Net Income Open source Share or cite Citation for Net Income · KALOBIOS PHARMACEUTICALS INC · 2022-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Net Income: -70730000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -70730000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#763710 Filing: 000121465923004512 The citation records this snapshot. The page link may show a newer release later.	−USD 76.7 million Exact value Exact value: -76698000 USD 2022-01-01 – 2022-12-31: -76698000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · KALOBIOS PHARMACEUTICALS INC · 2022-12-31 KALOBIOS PHARMACEUTICALS INC (edgar:1293310) Operating Cash Flow: -76698000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T12:33:07Z Snapshot: 930f173ffb3ac77230665bfffac4954989122e90e39822a9c838a1908ca4e394 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1293310/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76698000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1293310/000121465923004512/hgen-20221231.htm#770688 Filing: 000121465923004512 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

58 filings · 2,473 latest values · 2,473 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001293310, 1293310, HGEN, KALOP, KBIO, edgar:1293310

Also known as HUMANIGEN, INC, HUMANIGEN, INC., Humanigen, Inc, Humanigen, Inc., KALOBIOS PHARMACEUTICALS INC

KALOBIOS PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation